Impavido for Patient Care

Added: Apr 11, 2017 1:40 pm Modified: Apr 28, 2017 11:41 amTrack Changes Modification 0001 corrects the NAICS Code to 325412, Pharmaceutical Preparation Manufacturing.

This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. The National Institute of Health, Clinical Center (CC) intends to award a Firm Fixed Price Purchase Order to Profounda Inc., 5790 Hoffner Ave, Ste 507, Orlando, FL 32822-4824, on a sole source basis to procure Impavido ® (miltefosine)50 milligram capsules, as necessary to fulfill the requirements of the NIH Clinical Center. The Government intends to purchase a minimum of 3 boxes (84 capsules) with options to purchase additional quantities as required within a 12 month Period of Performance. The FDA granted the Impavido® application priority review status, which facilitates and expedites the development and review of certain drugs in light of their potential to benefit patients with serious or life-threatening conditions. Impavido® is available exclusively through the specialty pharmaceutical distributor, Profounda, Inc.
This acquisition is being conducted using policies unique to the acquisition of commercial items prescribed in FAR Part 12 in conjunction with the policies and procedures for the competition requirements in FAR Part 6. Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government.
Comments to this announcement, referencing this posting number, may be submitted to the CC, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention of Lisa Schaupp, Contract Specialist, Lisa.Schaupp@nih.gov, by the due date and time marked in this notice.